gimli
ASTRAZEN stock analysis context
ASTRAZENECA PHARMA IND LT Stock Context for AI Screening
ASTRAZENECA PHARMA IND LT is a small-cap stock in Healthcare. This page summarizes key screening signals for ASTRAZENECA PHARMA IND LT, including recent returns, momentum indicators, valuation ratios, liquidity, and growth metrics. Gimli uses this context to help users ask natural-language stock screening questions across Indian equities.
Open interactive ASTRAZEN stock pagePrice
₹8,141.00
1W return
-0.43%
1M return
-2.43%
3M return
+3.19%
6M return
-3.30%
1Y return
-10.80%
Market cap
₹20,352.50 cr
PE
108.54
PB
23.32
ROE
+22.82%
ROCE
+28.69%
RSI
41.22
Turnover
₹4.08 cr
Why it can matter in screens
- Momentum: ASTRAZEN is trend mixed or unavailable; RSI is 41.22.
- Returns: 1D -0.77%, 1W -0.43%, 1M -2.43%, 3M +3.19%, 1Y -10.80%.
- Trend levels: 52W high ₹9,827.50, 52W low ₹7,765.50, off high -17.16%.
- Liquidity: latest turnover is ₹4.08 cr; volume vs 20D is +0.72%.
- Valuation/profitability: PE 108.54, PB 23.32, ROE +22.82%, ROCE +28.69%.
- Growth: 3Y sales CAGR +31.39%, 3Y profit CAGR +23.60%.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 578.61 cr | 65.78 cr | 44.88 cr | 17.95 |
| 2025-12-31 | 611.57 cr | 51.44 cr | 32.59 cr | 13.04 |
| 2025-09-30 | 559.09 cr | 76.06 cr | 54.22 cr | 21.69 |
| 2025-06-30 | 526.31 cr | 91.99 cr | 55.83 cr | 22.33 |
| 2025-03-31 | 480.48 cr | 96.84 cr | 58.25 cr | 23.30 |
| 2024-12-31 | 440.29 cr | 51.42 cr | n/a | nan |
| 2024-09-30 | 408.00 cr | 60.69 cr | n/a | 15.37 |
| 2024-06-30 | 387.52 cr | -11.14 cr | -11.79 cr | -4.72 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 2,275.58 cr | 285.27 cr | 187.52 cr | 75.01 |
| 2025-03-31 | 1,716.29 cr | 197.81 cr | 115.74 cr | 46.30 |
| 2024-03-31 | 1,295.53 cr | 235.68 cr | 161.51 cr | 64.60 |
| 2023-03-31 | 1,002.97 cr | 150.99 cr | 99.29 cr | 39.70 |
| 2022-03-31 | 820.36 cr | 100.94 cr | 61.60 cr | 24.60 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 1,989.10 cr | 447.72 cr | 110.66 cr | 872.79 cr |
| 2025-03-31 | 1,518.12 cr | 536.14 cr | 35.73 cr | 770.35 cr |
| 2024-03-31 | 1,078.03 cr | 505.57 cr | 4.59 cr | 711.92 cr |
| 2023-03-31 | 984.87 cr | 500.34 cr | 7.21 cr | 588.69 cr |
| 2022-03-31 | 856.56 cr | 448.42 cr | 8.63 cr | 511.39 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | -15.14 cr | -18.75 cr | n/a |
| 2025-03-31 | 65.36 cr | 63.61 cr | n/a |
| 2024-03-31 | 27.87 cr | 17.11 cr | n/a |
| 2023-03-31 | 58.29 cr | 49.77 cr | n/a |
| 2022-03-31 | 100.80 cr | 91.18 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-03-31 | +75.00% | +2.78% | +5.80% | +5.66% | +16.42% | +0.00% |
| 2025-12-31 | +75.00% | +2.71% | +5.56% | +5.43% | +16.73% | +0.00% |
| 2025-09-30 | +75.00% | +2.74% | +5.26% | +5.00% | +17.00% | +0.00% |
| 2025-06-30 | +75.00% | +3.03% | +4.56% | +4.33% | +17.41% | +0.00% |
| 2025-03-31 | +75.00% | +2.89% | +4.65% | +4.45% | +17.46% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 453,042.43 cr | 39.400236 | +14.71% | +12.90% |
| DIVISLAB | DIVI S LABORATORIES LTD | 179,324.04 cr | 69.830233 | +16.19% | -2.64% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 164,701.07 cr | 76.144739 | +17.18% | +46.47% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 125,861.94 cr | 64.267738 | +21.03% | +15.71% |
| CIPLA | CIPLA LTD | 115,660.88 cr | 29.801362 | +11.79% | -3.80% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 115,515.66 cr | 23.036787 | +17.93% | +16.76% |
| LUPIN | LUPIN LIMITED | 112,429.39 cr | 21.054508 | +26.83% | +27.93% |
| DRREDDY | DR. REDDY S LABORATORIES | 112,317.04 cr | 26.207396 | +11.94% | +5.08% |
Try these prompts
- Analyze ASTRAZENECA PHARMA IND LT with valuation, momentum and industry peers
- Compare ASTRAZEN with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare ASTRAZEN with other Healthcare stocks
Data snapshot: 2026-07-08. Not investment advice.